Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
finafloxacin
- Development stage
- Approved
- Lead developer
- MerLion Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Otic
01
Overview
Finafloxacin is a fluoroquinolone antibiotic indicated for the treatment of acute otitis externa (swimmer's ear) caused by susceptible strains of *Pseudomonas aeruginosa* and *Staphylococcus aureus*. It is available as an otic (ear drop) formulation and works by inhibiting bacterial type II topoisomerase enzymes, specifically DNA gyrase and topoisomerase IV, which are essential for bacterial DNA replication, transcription, repair, and recombination. Finafloxacin demonstrates enhanced activity in acidic environments compared to other fluoroquinolones. The drug is marketed under the brand name Xtoro and was developed by Novartis.
- Brand names
- Xtoro
- Other names
- finafloxacin hydrochlorideGastrochinolonGastroquinolone
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)
Beyond the preview
Go deeper on finafloxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on finafloxacin.